東瑞製藥(02348.HK)中期淨利1.67億元 同比增加28.5%
格隆匯8月27日丨東瑞製藥(02348.HK)發佈公吿,截至2021年6月30日止6個月,公司實現收入6.09億元(人民幣,單位下同),同比增加24.5%;母公司擁有人應占期間溢利1.67億元,同比增加28.5%;基本每股盈利0.11127元;擬派中期股息每股0.015港元。
報吿期內,集團營銷部門深挖終端市場拓寬產品覆蓋範圍,成藥主要領域產品的銷售量與銷售收入與去年同期比較均有所上升。主因集團充分利用產品品牌優勢和市場營銷資源,各主要品種如苯磺酸氨氯地平片、氯沙坦鉀氫氯噻嗪片、鹽酸西替利嗪片、恩替卡韋分散片等專科藥物取得預期的銷售增長。
另外,集團前中選國家集採的四個品種,實際供應量持續位處高峯,銷售錄得高雙位數百分比同比增長。中間體和原料藥方面,因海外2019冠狀病毒病疫情反覆,影響出口業務運作效率,期間集團中間體和原料藥銷售與去年同期比較有所下降。
然而基於成藥分類溢利的良好基礎,期間集團收入與盈利與去年同期比較仍有所增長。若進一步審視2021年上半年與2020年下半年的業績,亦有雙位數百分比上升,可見本集團於過去一年整體營運與銷售趨勢積極向好。
產品研發方面,集團緊貼國家政策及本公司發展策略,建立新產品和新技術的研究方向與計劃,除堅持圍繞現有產品平台,自主開發更多相同治療領域的藥物外,亦合理利用外部研發資源加快建設在研產品管綫,納入其他治療領域的高端產品,更廣泛滿足患者需求。經過管理層與研發團隊共同悉心鋪墊,集團已漸次形成多層次的在研產品梯隊。期間已有完成研究品種獲准註冊上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.